2021 American Transplant Congress
Evaluation of Rituximab-abbs in Renal Transplant: A Case Series
*Purpose: Biosimilars are FDA-approved alternatives to cost-prohibitive biologics, with no clinically meaningful differences in safety, purity, and potency. Rituximab-abbs, a biosimilar to rituximab, has labeled…2021 American Transplant Congress
Comparing Bortezomib Protocol versus IVIG/Rituximab in the Treatment of Antibody Mediated Rejection (AMR) in Kidney Transplantation
*Purpose: To compare outcomes of historical treatment of AMR [PLEX + IVIG + Rituximab] with addition of bortezomib, along with characterizing safety parameters aimed at…2021 American Transplant Congress
Highly Sensitized Simultaneous Liver-kidney Transplant Recipients Show a Reduction in Panel Reactive Antibodies and No Kidney Rejection 1-year Post-transplant
Houston Methodist Hospital, Houston, TX
*Purpose: The liver is unique in that it is considered an immunologically tolerant organ against graft destruction by antibodies. Simultaneous liver-kidney transplantation (SLKT) are often…2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…2021 American Transplant Congress
Angiotensin II Type-1 Receptor Antibodies are Associated with Inferior Renal Allograft Survival
Renal Department, Imperial College Healthcare NHS Trust, London, United Kingdom
*Purpose: AT1R-antibodies have been implicated in antibody-mediated vascular rejection in the absence of detectable HLA donor specific antibody (DSA), in addition to cardiovascular diseases. Transplant…2021 American Transplant Congress
Late Subclinical Rejection and Borderline Rejection in Kidney Transplant Patients is Associated with Increased Incidence of Subsequent Clinical Rejections
*Purpose: The outcomes of inflammatory changes noted in late surveillance biopsies (1 year) is unclear.*Methods: Patients transplanted (live donor and deceased donor) at our center…2021 American Transplant Congress
Investigating the HLA Alloimmune Background of the Histological Changes Suggestive of Antibody-mediated Injury in the Absence of Donor-specific Anti-HLA Antibodies
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: The histology of antibody-mediated rejection is observed frequently after kidney transplantation, but a significant percentage of the patients do not have detectable donor-specific HLA…2021 American Transplant Congress
The Microenvironment of Belatacept-Resistant Rejection
Surgery, Emory University, Atlanta, GA
*Purpose: Belatacept is a co-stimulation blockade immunosuppressant, that despite demonstrating improved long-term outcomes, has not been widely adopted, in part, due to concern over early…2021 American Transplant Congress
Urinary Exosome Mrna Signature for the Diagnosis of Human Kidney Transplant Rejection
*Purpose: Traditional biomarkers currently used to monitor the kidney allograft, such as creatinine and proteinuria, are late markers of injury and lack sensitivity, specificity and…2021 American Transplant Congress
Impact of Donor and Recipient Age Difference: Outcomes within the First Year of Orthotopic Heart Transplant
Baylor St. Luke's Medical Center, Houston, TX
*Purpose: In recent history, the number of patients listed as eligible to receive a heart transplant has increased by nearly 40%. However, not all hearts…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 172
- Next Page »